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Abstract
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Brucellosis is an important zoonotic disease of nearly worldwide distribution. The occurrence of
the infection in humans is largely dependent on the prevalence of brucellosis in animal reservoirs,
including wildlife. The current vaccine used for cattle Brucella abortus strain RB51, has proven
ineffective in protecting bison (Bison bison) and elk (Cervus nelsoni) from infection and abortion.
To test possible improvements in vaccine efficacy, a novel approach of immunization was
examined from April 2004 to November 2006 using alginate composite microspheres containing a
nonimmunogenic, eggshell-precursor protein of the parasite Fasciola hepatica (Vitelline protein B,
VpB) to deliver live vaccine strain RB51. Red deer (Cervus elaphus), used as a model for elk,
were vaccinated orally (PO) or subcutaneously (SC) with 1.5×1010 viable organisms per animal.
Humoral responses postvaccination (immunoglobulin G [IgG] levels), assessed at different time
points, indicated that capsules containing live RB51 elicited an anti-Brucella specific IgG
response. Furthermore, the encapsulated vaccine elicited a cell-mediated response that the
nonencapsulated vaccinates failed to produce. Finally, red deer were challenged with B. abortus
strain 19 by conjunctival exposure. Only animals that received encapsulated RB51 vaccine by
either route exhibited a significant reduction in bacterial counts in their spleens. These data
suggest that alginate-VpB microspheres provide a method to enhance the RB51 vaccine
performance in elk.
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INTRODUCTION
Brucella abortus is a facultative, intracellular, gram-negative, bacterial pathogen and the
etiologic agent of brucellosis, an important zoonoses with a nearly worldwide distribution
(Boschiroli et al., 2001). Human brucellosis, a debilitating disease characterized by
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fluctuating fever, is caused mainly by contamination from infected ruminants or
consumption of contaminated animal products. Moreover, the disease is a major cause of
direct economic losses (Corbel, 1997) and a barrier for international trade of live animals.
Brucella spp. are also considered a class III pathogen and classified as potential bioterrorist
agents.
Brucellosis eradication programs in North America have been successful in controlling the
pathogen in domestic livestock but not in wildlife populations (Ragan, 2002). Currently, elk
(Cervus elaphus nelsoni) and bison (Bison bison) are the wildlife reservoirs of B. abortus in
the Greater Yellowstone area, and transmission from wildlife to cattle has occurred (Thorne,
1980).
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Effective vaccines to control brucellosis in wildlife are not currently available.
Commercially available vaccine strains used for brucellosis eradication in cattle have been
tested in wildlife species (Davis and Elzer, 2002), but results from elk vaccination trials
have shown that efficacy is reduced in comparison to cattle. Additional vaccination-related
problems include interference with diagnosis (Schurig et al., 2002), resistance to antibiotics,
and potential virulence for animals and humans (Berkelman, 2003; Ashford et al., 2004).
The B. abortus strain 19 (S19) appeared to be safe in adult elk but has been shown to reduce
abortion rates only by 30% (Thorne et al., 1981). The S19 vaccine also does not cause
morbidity or mortality in pronghorn antelope (Antilocapra americana; Elzer et al., 2002),
bison (Davis et al., 1991) or coyotes (Canis latrans). Another Brucella vaccine, SRB51, has
been shown to be safe in a wider range of nontarget species, including ravens (Corvus
corax), Richardson ground squirrels (Spermophilus richardsonii), and deer mice
(Peromyscus maniculatus; Januszewski et al., 2001); bighorn sheep (Ovis canadensis),
pronghorn antelope, mule deer (Odocoileus hemionus), and moose (Alces alces shirasi;
Kreeger et al., 2002b); and black bears (Ursus americanus; Olsen et al., 2004). However, if
administered parenterally, SRB51 did not protect against abortion in elk (Cook et al., 2002;
Kreeger et al., 2002a).
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The distribution of the disease appears to be correlated with high animal densities associated
with winter feeding (Etter and Drew, 2006). Infected and susceptible elk commingling on
feed grounds ensure exposure of animals to B. abortus, enhancing the probability of
transmission. Control of brucellosis should be focused on these sites to prevent or reduce
exposure of the pathogen to naïve animals, thus breaking the chain of transmission.
Difficulties with integrating Brucella vaccination strategies into control efforts have been
associated not only with the low efficacy of S19 and RB51 in elk but also with the delivery
method used to immunize the animals. Currently, elk vaccination uses a S19 biobullet
ballistic approach, and problems arising from this methodology include excessive time and
labor, logistics, and high cost.
During April 2004 to November 2006, we evaluated the potential for delivering a live RB51
vaccine to elk via a controlled microencapsulated release vehicle. The capsule was made of
alginate, a naturally occurring biopolymer that offers the advantages of biocompatibility,
low toxicity, and encapsulation conditions that are compatible with live organisms (Wee and
Gombotz, 1998). In an attempt to enhance the efficacy of the capsule, we also incorporated a
novel protein from the eggshell precursor of the parasite Fasciola hepatica, Vitelline protein
B (VpB). This recombinant 31-kDa protein possesses an unusual resistance to proteolytic
breakdown (Rice-Ficht et al., 1992), which may reduce erosion time and release of the
capsule content. To further explore the alternatives of using this method, PO delivery of the
microencapsulated vaccine was also investigated, principally because this is the most costeffective way to deliver a vaccine in wildlife populations.
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MATERIALS AND METHODS
Animals

NIH-PA Author Manuscript

Fifty-four 1–2-yr-old red deer (Cervus elaphus elaphus) females from a privately owned
tuberculosis-free and brucellosis-free commercial herd were used as an animal model for
Rocky Mountain elk (Cervus elaphus nelsoni) because of their close genetic relationship.
Upon arrival, animals were retested for specific anti-Brucella immunoglobulin G (IgG)
levels (total IgG) by enzyme-linked immunosorbent assay (ELISA) and were dewormed
(moxidectin, Cydectin; Wyeth, Madison, New Jersey, USA). Deer were acclimated for 3 mo
before vaccination. All animal care and experimental procedures were performed in
compliance with the institutional animal-care protocol.
Bacterial strains
Bacterial strains used in these experiments included the vaccine strains SRB51 and S19.
Bacteria were grown on tryptic soy agar (TSA; Difco, BD, Sparks, Maryland, USA) at 37 C
with 5% CO2. Three days postincubation, SRB51 plates were harvested and bacteria were
pelleted and standardized for subcutaneous or PO vaccination at a dose of 1.5×1010, whether
encapsulated or nonencapsulated. For animal challenge, a dose of 1×109 of vaccine S19 was
standardized using a klett meter and plating onto TSA plates retrospectively to confirm the
dose.
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Preparation of B. abortus SRB51 antigen-loaded microspheres
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Alginate beads, loaded with 1.5×1010 colony-forming units (cfu)/ml of the vaccine SRB51,
were prepared as previously described (Abraham et al., 1996) with some modifications.
Briefly, enumerated, live SRB51 vaccine strain (total 1.5×1011 for 10 doses) was
resuspended in a total of 100 μl of 3-(N-morpholino) propanesulfonic acid (MOPS) buffer
(10mM MOPS, 0.85% NaCl, pH 7.4) and mixed with 10 ml of alginate solution (1.5%
sodium alginate, 10mM MOPS, 0.85% NaCl, pH 7.3). Spheres (300 μm) were obtained by
extruding the suspension through a 200-μm nozzle into a 100 mM calcium chloride solution
that was stirred for 15 min using an Inotech encapsulator I-50 (Inotech Biosystems
International, Rockville, Maryland, USA). For a permanent cross-linking of the capsule,
microspheres were washed three times with 200 ml of MOPS buffer for 10 min and further
stirred in a solution containing 0.05% poly-L-lysine (molecular weight = 22,000) for 15 min.
Following two successive washes, the beads were stirred in a solution of 0.03% alginate for
5 min to apply a final outer coating. All capsules were stored at 4 C in MOPS buffer until
use. To determine the number of bacteria per 1 ml of capsules, spheres were removed from
the encapsulator before the permanent cross-linking and were washed three times with 50 ml
of MOPS buffer, and particles were dissolved using 10 ml of depolymerization solution
(50mM sodium citrate, 0.45% NaCl 10mM MOPS, pH 7.2). Enumeration of bacteria was
determined by plating onto TSA plates.
The addition of VpB as a component of the alginate core was achieved by the addition of 1
mg of VpB to the bacteria-alginate suspension described above. Extrusion and capsule
formation used the same preparation conditions.
Immunization of red deer
Fifty-four 1–2-yr-old, female red deer were randomly distributed into six different
treatments (n = 9/group). Three groups were inoculated subcutaneously with a total dose of
1.5×1010 cfu of either nonencapsulated SRB51, encapsulated SRB51 with alginate, or
encapsulated RB51 with alginate and VpB. Two groups were vaccinated by the PO route by
squirting the vaccine into their mouth; one group received 1.5×1010 cfu of encapsulated
SRB51 with alginate, and the second group received with encapsulated RB51 with alginate
J Wildl Dis. Author manuscript; available in PMC 2012 May 13.
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and VpB. The control group received a subcutaneous injection of 1 ml of empty capsules
(no bacteria entrapped). A single vaccination dose was given to all animals.
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Detection of Brucella-specific antibody levels
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Lymphocyte proliferation assay from peripheral blood mononuclear cells

To determine anti-Brucella–specific antibody in serum, blood samples were collected by
jugular venipuncture immediately before vaccination and 6, 12, 17, and 28 wk
postvaccination. Serum samples were analyzed for anti-Brucella IgG (total IgG)
determination by ELISA. Heat-killed SRB51 cell antigen was used to coat 96-well plates
(Nunc-Immuno plates, high binding protein; Thermo Fisher Scientific, Rochester, New
York, USA) at a concentration of 25 μg/well. After overnight incubation at 4 C, plates were
washed using phosphate-buffered saline (PBS) containing 0.05% Tween-20, blocked (0.25%
w/v bovine serum albumin), and incubated with the diluted deer-serum samples (1:100 in
blocking buffer) for 2 hr. Following three more washes, goat anti-deer IgG horseradish
peroxidase (KPL Systems, Silver Spring, Maryland, USA) conjugate was added at a dilution
of 1:1,000 and incubated at room temperature for 1 hr. After incubation, plates were washed,
and o-phenylenediamine dihydrochloride per-oxidase substrate (Sigma-Aldrich, St. Louis,
Missouri, USA) was added following manufacturer’s instructions for 20 min. The reaction
was stopped by the addition of 50 μl of 0.5M NaOH. The absorbance was measured at 450
nm (A450). All assays were performed in triplicate and repeated at least two times.

At 12 wk postvaccination, mononuclear cells were isolated from peripheral-blood buffy
coats as previously described (Waters et al. 2002) with some modifications. Briefly, 2×105
cells/well were seeded in 96-well plates (Falcon, Becton Dickinson, San Jose, California,
USA) in RPMI medium containing 10% (v/v) fetal bovine serum, 1mM L-glutamine, and
1mM nonessential amino acids. Cells were stimulated, with B. abortus wild-type S2308
lysate at a concentration of 12.5 μg/ml, concanavalin A (5 μg/ml), or medium alone, and
were incubated for 6 days at 37 C with 5% CO2. After this incubation period, 1 μCi of
methyl-[3H] thymine was added to each well. Following 18 hr of incubation, cells were
harvested onto fiber filters using a 96-well plate cell harvester, and the incorporated
radioactivity was measured by liquid-scintillation counting. Lymphocyte proliferation data
is represented as mean counts per minute (cpm) ± standard deviation.
Host response to subsequent B. abortus S19 exposure
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At 7 mo postvaccination, three to four animals from each vaccination group (except RB51/
alginate SC; n = 2) were exposed conjunctivally, as previously described (Kreeger et al.,
2000), using a challenge dose of 1×109 cfu/deer of B. abortus S19. Dose exposure was
confirmed by serial dilutions and plating onto TSA plates. At 2 wk post-challenge, animals
were euthanized, and spleens were harvested, weighed and homogenized. For
homogenization, 1 ml of peptone saline was added to 1 g of tissue. Each sample was treated
for 5–10 min using a stomacher. From each sample, 100 μl was plated onto Farrell’s media
(Oxoid LTD, Basingstoke, Hampshire, England) in duplicate. At 3–5 days postincubation,
bacteria were enumerated. Results are represented as the mean cfu/g of tissue ± standard
error of the mean (SEM).
Statistical procedures
Anti-Brucella IgG levels elicited from vaccination were expressed as the mean absorbance
at 450 ± SD for each group. For lymphocyte proliferation, the cpm from each group were
expressed as the mean cpm ± SD. Bacterial load from S19 challenge was expressed as mean
log cfu ± SEM for each group. The significance of differences between groups was
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determined by analysis of variance (ANOVA); a P value <0.05 was considered statistically
significant.
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RESULTS
Encapsulation of B. abortus SRB51 in alginate microspheres
Two different capsular formulations were prepared using the same alginate base. Variation
of the formulation included the addition of VpB within the capsule to modify the
degradation kinetics and release of the organism. When capsules were analyzed using light
microscopy, all of the capsule formulations appeared spherical and uniform with a mean
diameter of 310 μm (Fig. 1). Furthermore, bacterial viability following encapsulation
exceeded 95%, as demonstrated by recovery of the organism following dissolution of the
capsules (data not shown).
Cellular immune response
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At 12 wk postvaccination, animals that received the encapsulated vaccine with VpB in the
formulation (regardless of the immunization route) were the only individuals that had a
statistically significant proliferative response compared with the controls (P<0.0005 PO
vaccinates, P<0.005 SC group; Fig. 2). Interestingly, the cpm counts in animals that received
encapsulated RB51 with VpB PO were also higher than in deer that received the same
formulation via SC (P<0.3). None of the animals that received nonencapsulated vaccine had
a significant cellular response compared with naïve nonvaccinated animals.
Anti-Brucella IgG response
Immunization with RB51 elicited an anti-Brucella IgG response that was clearly detectable
by 6 wk postvaccination (Fig. 3). During the initial 17 wk, anti-Brucella IgG levels were
higher in animals that received the injected vaccine compared with the groups that were
immunized PO (P<0.05). Between 17 to 28 wk, anti-Brucella IgG levels in animals that
were PO-vaccinated had an increase in anti-Brucella IgG compared with deer SCvaccinated.
Host response against challenge by conjunctival S19 exposure
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The host protective response was determined by subtracting the mean cfu of S19 recovered
per gram of spleen from deer vaccinated with the nonencapsulated or encapsulated vaccine
from the mean cfu per gram recovered from naïve non-vaccinated but infected deer. At 2 wk
postchallenge, only animals that received encapsulated SRB51 with VpB had a significant
decrease in bacterial load in the spleen (Fig. 4). Red deer that received the vaccine PO were
the only group that was statistically significant compared with the nonencapsulated, injected
SRB51 (P<0.04). Animals that were PO-immunized with the VpB capsules had a 1.27 log
reduction in spleen counts compared with animals vaccinated with nonencapsulated SRB51
and a 1.68 log reduction compared with naïve, nonvaccinated, but S19 exposed, animals.
Brucella abortus strain 19 spleen counts in deer that received the VpB capsules via SC were
also diminished by 1.21 log compared with the nonencapsulated RB51 and by 1.62 log
compared with non-SRB51 vaccinated controls (P<0.2).

DISCUSSION
The ultimate goals of vaccination are to control disease and reduce or eliminate transmission
from reservoir species. To accomplish these goals in elk using current Brucella vaccines, the
development of more efficacious vaccination mechanisms are needed to enhance vaccine
efficacy.
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Recent data indicate that the manner in which antigen reaches the lymph organs and how it
is delivered to the antigen-presenting cells are fundamental in the induction of an optimal
immune response. There is experimental evidence to support the observation that
microencapsulation serves to modify the uptake and processing of antigen (Eyles et al.,
2001; Sun et al., 2003). Also, it has been suggested that prolonged persistence of the vaccine
strain in the host is needed for the development of a suitable anti-Brucella immunity (KahlMcDonagh and Ficht, 2006). In an effort to develop a more efficient way to present the
current vaccine SRB51 to the lymphoid tissue and to increase the exposure time of the
organism to the host cells, we developed a controlled-release strategy in which SRB51 was
encapsulated into alginate-VpB composite microspheres. We were successfully able to
entrap SRB51 and develop uniform spherical batches of capsules, even when VpB was
added to the formulation. By adding this component to the capsules, we modified the
efficiency of the capsule as demonstrated by the difference in cellular and humoral
responses observed in animals that received this formulation.
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Live vaccines are more efficacious than vaccination with heat-killed organisms or cellular
extracts and provide a significant level of immunity for protection against brucellosis (Zhan
et al., 1995; Schurig et al., 2002). During microsphere formulation, SRB51 was exposed to
relatively mild conditions that preserved bacterial viability (95%). This is in contrast to
many standard encapsulation procedures, which employ harsh conditions to affect
polymerization, including direct exposure of the bacteria to organic solvents, shear stress,
and ultrasound homogenization (Lima and Rodrigues, 1999).
Oral bait administration of vaccines is the most practical and cost-effective method to
vaccinate wildlife, and successful techniques and strategies for PO immunization of foxes
(Vulpes vulpes) against rabies have been extensively demonstrated (Schneider, 1995;
Pastoret and Brochier, 1996). Many pathogens, including Brucella spp, access the body via
the mucosal surfaces; neutralization of the microorganism at the mucosal site would be an
ideal situation to prevent brucellae from infecting the host. Our data indicate that increased
efficacy with current Brucella vaccine strains can be achieved if the antigens are presented
PO in a controlled-release format. The composite micro-spheres may serve to enhance the
viability of bacteria in the ruminant digestive tract while providing immunization in a
controlled-release format. The capsule might also provide a vaccine package that could be
combined with baits for easy delivery.
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Humoral immunity was assessed within all the SRB51 vaccine formulations and routes of
vaccination. Immunization with SRB51 induced elevated anti-Brucella IgG levels (total
IgG); however, levels were lower in deer vaccinated with the nonencapsulated vaccine than
those induced by the microcapsules. In PO vaccinates, increasing levels of IgG between 17
to 28 wk were observed, which may reflect the protective benefits of the capsule for the live
vaccine during exposure to conditions in the digestive tract. It is important to mention that
all groups except controls, had increased levels of anti-Brucella IgG. Only the PO RB51
vaccinated groups had statistically significant increase compared with deer vaccinated via
SC (P<0.05). The overall increases observed in all groups may have been associated with
the seasonal hormonal cycles in deer.
Induction of specific cell-mediated immune responses following immunization is a hallmark
for the establishment of a protective immune response. In elk, both cellular and humoral
responses might be needed to generate a strong immunity toward Brucella infections
(Kreeger et al., 2002a). Our results with the encapsulated SRB51 indicated that by 12 wk
alginate/ VpB capsules administered SC or PO stimulated a statistically significant higher
cellular response compared with nonencapsulated SRB51. These data suggest that by
incorporating the SRB51 vaccine into a delivery vehicle, the necessary conditions needed to
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trigger a protective cellular response are created. Moreover, a low cellular response elicited
by nonencapsulated RB51 was observed, corroborating the results previously reported by
other researchers (Cook et al., 2002; Kreeger et al., 2002a).
After the initial cellular and humoral responses were assessed, three or four animals from
each group were challenged with S19 to determine the degree of protection conferred by the
encapsulated vaccine to subsequent Brucella exposure. This strain was used because it has
been previously shown that S19, by itself, is able to cause prolonged infection in deer and
can be cultured from the spleen by 2 wk postinoculation. Using a challenge dose of 1×109
cfu, a significantly (P<0.04) lower infection rate was observed in animals that were
immunized with the encapsulated vaccine. This was especially true for deer that received
VpB in the formulations. In the case of PO vaccination, results not only corroborate the
observed cellular and humoral responses but also support our idea that the capsule serves as
a vehicle necessary for proper immunogenicity. The fact that reduction of infection was
afforded to such a degree via PO delivery is highly promising and relevant to the current
needs for a practical vaccination strategy. Further investigations with a higher number of
animals, and actual challenge with wild-type organisms, are still needed.
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In summary, our findings indicate that alginate-VpB encapsulation of live Brucella might be
used not only to enhance vaccine efficacy in elk but also to provide a practical means of
vaccination. Enhanced immune responses were observed in red deer that were vaccinated
with encapsulated formulations, especially containing the VpB additive. Oral vaccination
with VpB encapsulated formulations was able to invoke both humoral- and cell-mediated
responses in red deer and to offer protection from a challenge of live S19, as evidenced by
organism recovery from the spleen. These data support the hypothesis that an enhanced and
prolonged host response because of a mucosal immune stimulation can be achieved via PO
vaccination. Finally, the results observed using nonencapsulated RB51 were similar to those
obtained in previous studies (Olsen et al., 2002) in which RB51, by itself, is not sufficient to
induce a good cellular response or reduce infection in elk (Kreeger et al., 2002a) to a
significant degree.
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Figure 1.

Light microscopy image of alginate-vitelline protein B (VpB) microspheres loaded with the
vaccine strain SRB51. Brucella abortus SRB51 was encapsulated into alginate microspheres.
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Figure 2.

Immunoglobulin G (IgG) anti-Brucella antibodies in serum from deer vaccinated with
SRB51. Red deer (n = 9/group) were inoculated subcutaneously (SC) with 1.5×1010 colonyforming units (cfu) of either nonencapsulated SRB51, encapsulated SRB51, or encapsulated
SRB51 with vitelline protein B (VpB). Control group received empty capsules. Two groups
received encapsulated oral (PO) vaccine (SRB51 with alginate or SRB51 with VpB) at the
same dose. At 0, 6, 12, 17, and 28 wk postvaccination, serum samples were collected and
analyzed for anti-Brucella IgG determination by enzyme-linked immunosorbent assay
(ELISA). Results are shown as the means ± standard deviations of absorbance at 450 nm.
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Lymphocyte-proliferative responses of peripheral blood mononuclear cells from deer
immunized with RB51. Red deer (n = 9/group) were vaccinated subcutaneously (SC) with
1.5×1010 colony-forming units (cfu) of either nonencapsulated SRB51, encapsulated SRB51
(SRB51 with alginate), or encapsulated SRB51 with vitelline protein B (VpB). Two groups
received encapsulated, oral (PO) vaccine (SRB51 with alginate or SRB51 with VpB) at the
same dose. Control group received empty capsules. Results are expressed as mean counts
per minute (cpm) ± standard deviation (SD). * P<0.005 are statistically different from the
control by analysis of variance (ANOVA).
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Figure 4.

Host response against S19 challenge. Red deer received either oral (PO) or subcutaneous
(SC) vaccine, and 7 mo postvaccination animals were conjunctivally infected with 1×109
colony-forming units (cfu) of S19. At 2 wk postinfection, animals were euthanized, and
spleens were harvested. Values are reported as the mean log10 recovery of S19 from spleens.
Difference in colonization between the vaccinated and control animals was determined by
analysis of variance (ANOVA). * P<0.05.
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